Valeant (VRX) Price Target Raised to $200 at Deutsche Bank, Hold Maintained
Tweet Send to a Friend
Deutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) and raised its price target to $200.00 (from $141.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
